Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2019 Q2- Text added to 2019 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
appointed, atezolizumab, Azitra, BA, Beloff, bridging, Carnegie, CFO, College, concurrent, Danforth, DGCL, discontinue, discontinued, discontinuing, doctrine, duty, enumerated, fiduciary, fullest, Gregg, IP, JD, lymphoma, MBA, Mellon, Middlebury, monotherapy, Pittsburgh, randomized, Repair, School, serving, Shegog, solid, successor, Tecentriq, thereunder, Todd, Trucode, University, waived
Removed:
AB, Acer, Aeglea, AG, ApS, Bausch, behavioral, Cognition, cognitive, coma, consistency, cycle, discouraging, encephalopathy, expedited, Food, hepatic, Horizon, Kaleido, liver, Mallinckrodt, neurocognitive, Pharma, plc, Rebiotix, Selecta, tolerability, Translate, UCD, Ultragenyx, Umecrine, urea
Valuein 2019 Q2 filing- Value in 2019 Q3 filing
Original filings
Filing view